ArticleEmerging infectious diseases2026
New 2030 Global Targets for Histoplasmosis from International Society for Human and Animal Mycology (ISHAM) 2025 Histoplasmosis Working Group.
Article in Emerging infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
49 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Histoplasmosis remains a neglected yet deadly fungal infection, disproportionately affecting persons living with HIV/AIDS and other immunocompromised populations in endemic regions. Despite the World Health Organization's designation of Histoplasma as a high-priority pathogen, the disease remains underdiagnosed and excluded from national surveillance systems, resulting in delayed treatment and high death rates. To coordinate a global response, the International Society for Human and Animal Mycology convened a Histoplasmosis Working Group during its 2025 congress in Brazil. Experts engaged in structured discussions across 5 domains: awareness, research, diagnostics and treatment, capacity building, and fungal biology. The group highlighted persistent diagnostic delays, underuse of antigen testing, and poor access to liposomal amphotericin B and itraconazole. Innovations such as lateral flow assays and molecular tools were discussed, alongside the need for biobanks and validated diagnostic algorithms. A global 90-90-90 target for histoplasmosis by 2030 was proposed to improve diagnosis, treatment, and survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.